JP2020105193A5 - - Google Patents

Info

Publication number

JP2020105193A5

JP2020105193A5 JP2020036331A JP2020036331A JP2020105193A5 JP 2020105193 A5 JP2020105193 A5 JP 2020105193A5 JP 2020036331 A JP2020036331 A JP 2020036331A JP 2020036331 A JP2020036331 A JP 2020036331A JP 2020105193 A5 JP2020105193 A5 JP 2020105193A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

antigen

antibody

composition according

binding fragment

Prior art date

2020-03-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 35
• 239000000427 antigen Substances 0.000 claims 31
• 102000036639 antigens Human genes 0.000 claims 31
• 108091007433 antigens Proteins 0.000 claims 31
• 239000012634 fragment Substances 0.000 claims 31
• 238000012423 maintenance Methods 0.000 claims 17
• 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 15
• 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 15
• 208000006673 asthma Diseases 0.000 claims 15
• 229940125389 long-acting beta agonist Drugs 0.000 claims 11
• PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 10
• 238000011282 treatment Methods 0.000 claims 10
• 208000024891 symptom Diseases 0.000 claims 7
• 238000002648 combination therapy Methods 0.000 claims 5
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
• 230000001800 adrenalinergic effect Effects 0.000 claims 4
• 229940125369 inhaled corticosteroids Drugs 0.000 claims 4
• 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 4
• 210000004027 cell Anatomy 0.000 claims 3
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
• 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
• 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 2
• 102000057955 Eosinophil Cationic Human genes 0.000 claims 2
• 101710191360 Eosinophil cationic protein Proteins 0.000 claims 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 2
• 239000000090 biomarker Substances 0.000 claims 2
• 210000003979 eosinophil Anatomy 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
• 102000006440 Chemokine CCL26 Human genes 0.000 claims 1
• 108010083698 Chemokine CCL26 Proteins 0.000 claims 1
• 102000019034 Chemokines Human genes 0.000 claims 1
• 108010012236 Chemokines Proteins 0.000 claims 1
• 102100038196 Chitinase-3-like protein 1 Human genes 0.000 claims 1
• 238000013313 FeNO test Methods 0.000 claims 1
• 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 claims 1
• 102100037765 Periostin Human genes 0.000 claims 1
• 101710199268 Periostin Proteins 0.000 claims 1
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
• 230000004913 activation Effects 0.000 claims 1
• 208000037883 airway inflammation Diseases 0.000 claims 1
• 229960004436 budesonide Drugs 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 239000003246 corticosteroid Substances 0.000 claims 1
• 230000003292 diminished effect Effects 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 229950003468 dupilumab Drugs 0.000 claims 1
• 230000005713 exacerbation Effects 0.000 claims 1
• 229960000289 fluticasone propionate Drugs 0.000 claims 1
• WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
• 229960002848 formoterol Drugs 0.000 claims 1
• BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
• 210000004907 gland Anatomy 0.000 claims 1
• 238000001119 image correlation spectroscopy Methods 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 230000007774 longterm Effects 0.000 claims 1
• 230000004199 lung function Effects 0.000 claims 1
• 229960002744 mometasone furoate Drugs 0.000 claims 1
• WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
• 230000001105 regulatory effect Effects 0.000 claims 1
• 229960004017 salmeterol Drugs 0.000 claims 1
• 150000003431 steroids Chemical class 0.000 claims 1
• 239000000021 stimulant Substances 0.000 claims 1
• 230000009885 systemic effect Effects 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 210000000115 thoracic cavity Anatomy 0.000 claims 1